rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Infectious Diseases

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15688284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

  2004cited by this paper
• Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

  2004cited by this paper
• A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys

  2004cited by this paper
• Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.

  2003cited by this paper
• Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.

  2003cited by this paper
• Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

  2003cited by this paper
• Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

  2003cited by this paper
• Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

  2003cited by this paper
• Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

  2003cited by this paper
• A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

  2003cited by this paper
• Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

  2002cited by this paper
• Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

  2002cited by this paper
• Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

  2001cited by this paper
• Human Dendritic Cells Are Activated by Dengue Virus Infection: Enhancement by Gamma Interferon and Implications for Disease Pathogenesis

  2001cited by this paper
• Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

  2001cited by this paper
• A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.

  2001cited by this paper
• Evolutionary Relationships of Endemic/Epidemic and Sylvatic Dengue Viruses

  2000cited by this paper
• Live attenuated tetravalent dengue vaccine.

  2000cited by this paper
• Human skin Langerhans cells are targets of dengue virus infection

  2000cited by this paper
• Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

  2000cited by this paper
• Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine

  2000cited by this paper
• Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes

  1997cited by this paper
• Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.

  1997cited by this paper
• Molecular evolution and phylogeny of dengue-4 viruses.

  1997cited by this paper
• Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys

  1996cited by this paper
• Cytotoxic Factors Released by Dengue Virus‐Infected Human Blood Monocytes

  1995cited by this paper
• Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients.

  1993cited by this paper
• Correlation of E protein binding with cell susceptibility to dengue 4 virus infection.

  1992cited by this paper
• Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.

  1990cited by this paper
• A prospective study of dengue infections in Bangkok.

  1988cited by this paper
• Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers.

  1987cited by this paper
• Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.

  1987cited by this paper
• Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean.

  1986cited by this paper
• Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.

  1984cited by this paper
• Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever.

  1980cited by this paper
• Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection

  1977cited by this paper
• Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

  1958cited by this paper
• Recent advances in our knowledge of dengue and sandfly fever.

  1955cited by this paper
• PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE

  1945cited by this paper

• From promise to pitfalls: immunological lessons from dengue vaccines and their implications.

  2026cites this paper
• Human T Cell Responses to Flavivirus Vaccines

  2025cites this paper
• Dengue Vaccines.

  2025cites this paper
• Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles

  2024cites this paper
• Antiviral and antimicrobial applications of chalcones and their derivatives: From nature to greener synthesis

  2023cites this paper
• The dengue virus 4 component of NIAID’s tetravalent TV003 vaccine drives its innate immune signature

  2022cites this paper
• Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

  2021cites this paper
• Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus

  2021cites this paper
• A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans

  2021cites this paper
• Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model

  2021cites this paper
• Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans

  2020cites this paper
• Anti-dengue Vaccines: From Development to Clinical Trials

  2020cites this paper
• Dengue virus 4: the ‘black sheep’ of the family?

  2020cites this paper
• Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

  2020cites this paper
• Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade

  2020cites this paper
• The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek

  2019cites this paper
• Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines

  2019cites this paper
• Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.

  2018cites this paper
• Dengue viruses and promising envelope protein domain III-based vaccines

  2018cites this paper
• Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine

  2018cites this paper
• The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus

  2017cites this paper
• Vaccines licensed and in clinical trials for the prevention of dengue

  2017cites this paper
• Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

  2016cites this paper
• Dengue vaccines: Are they safe for travelers?

  2016cites this paper
• The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

  2016cites this paper
• Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

  2016cites this paper
• Zika virus produces noncoding RNAs using a multi-pseudoknot structure that confounds a cellular exonuclease

  2016cites this paper
• Trials and tribulations on the path to developing a dengue vaccine.

  2015cites this paper
• Tackling dengue fever: Current status and challenges

  2015cites this paper
• The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

  2015cites this paper
• Trials and Tribulations on the Path to Developing a Dengue Vaccine.

  2015cites this paper
• Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

  2015cites this paper
• Dengue human infection models to advance dengue vaccine development.

  2015cites this paper
• Advances in the understanding, management, and prevention of dengue.

  2015cites this paper
• Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.

  2015cites this paper
• The dengue vaccine pipeline: Implications for the future of dengue control.

  2015influential citation
• WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development.

  2015cites this paper
• Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.

  2014cites this paper
• Recent progress in dengue vaccine development

  2014cites this paper
• Dengue virus vaccine development.

  2014cites this paper
• Developing a dengue vaccine: progress and future challenges

  2014cites this paper
• Dengue Type Four Viruses with E-Glu345Lys Adaptive Mutation from MRC-5 Cells Induce Low Viremia but Elicit Potent Neutralizing Antibodies in Rhesus Monkeys

  2014cites this paper
• Understanding the Dengue Viruses and Progress towards Their Control

  2013cites this paper
• Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

  2013cites this paper
• The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

  2013cites this paper
• Challenges in reducing dengue burden; diagnostics, control measures and vaccines

  2013cites this paper
• A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

  2013cites this paper
• Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

  2013cites this paper
• Rational Discovery of Dengue Type 2 Non‐Competitive Inhibitors

  2013cites this paper
• Dengue vaccines: recent developments, ongoing challenges and current candidates

  2013cites this paper
• Immunologic hypo- or non-responder in natural dengue virus infection

  2013cites this paper
• Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization

  2012cites this paper
• Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans

  2012cites this paper
• Advances in the development of vaccines for dengue fever

  2012cites this paper
• THESIS MODELING DENGUE VIRAL INFECTION, INSECT TRANSMISSION AND MULTIPLEX PCR IN HUMANIZED MICE Submitted by Jennifer Suzanne Arab Graduate Degree Program in Cell and Molecular Biology In partial fulfillment of the requirements

  2012cites this paper
• Animal Models of Dengue Virus Infection

  2012cites this paper
• Next generation dengue vaccines: a review of candidates in preclinical development.

  2011cites this paper
• Issues Related to Recent Dengue Vaccine Development

  2011cites this paper
• Dengue Type 4 Live-Attenuated Vaccine Viruses Passaged in Vero Cells Affect Genetic Stability and Dengue-Induced Hemorrhaging in Mice

  2011cites this paper
• A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial

  2011cites this paper
• Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

  2011cites this paper
• Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

  2011cites this paper
• Vaccination and antiviral treatment of neglected diseases caused by flaviviral infections.

  2011cites this paper
• Immune response to dengue virus and prospects for a vaccine.

  2011cites this paper
• Vaccines for the prevention of dengue: Development update

  2011cites this paper
• A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies

  2011cites this paper
• Functions and requirements of conserved RNA structures in the 3’ untranslated region of Flaviviruses

  2011cites this paper
• Diagnosis and Prognosis of Severe Dengue

  2011cites this paper
• Dengue: a continuing global threat

  2010cites this paper
• Targeted mutagenesis as a rational approach to dengue virus vaccine development.

  2010cites this paper
• Dengue vaccine candidates in development.

  2010cites this paper
• Control of dengue virus translation and replication.

  2010cites this paper
• Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas

  2010cites this paper
• Dengue vaccines: state of the art

  2010cites this paper
• Knowledge, attitudes and practices regarding dengue infection in Westmoreland, Jamaica.

  2010cites this paper
• Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

  2009cites this paper
• Dengue: recent advances in biology and current status of translational research.

  2009cites this paper
• Pathogenesis and prevention of dengue virus infection: state-of-the-art

  2009cites this paper
• Dengue vaccine development and dengue viral neutralization and enhancement assays

  2009cites this paper
• [Vaccines for the future].

  2009cites this paper
• Progress towards a dengue vaccine.

  2009cites this paper
• Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

  2009cites this paper
• Advances in dengue vaccine development

  2009cites this paper
• Dengue: patogénesis y estado actual del desarrollo de vacunas Recibido: 9 de octubre de 2008

  2009cites this paper
• Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

  2008cites this paper
• Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses.

  2008cites this paper
• Dengue vaccines for travelers

  2008cites this paper
• Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

  2008cites this paper
• Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

  2008cites this paper
• Development of Improved Dengue 2 Antigen Configurations for a Venezuelan Equine Encephalitis Virus Replicon Particle-Launched Dengue Vaccine

  2008cites this paper
• Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.

  2008cites this paper
• Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.

  2008cites this paper
• Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2.

  2008cites this paper
• Antigenic relationships between sylvatic and endemic dengue viruses.

  2008cites this paper
• Prospects for a dengue virus vaccine

  2007cites this paper
• Attenuated dengue 2 viruses with deletions in capsid protein derived from an infectious full-length cDNA clone.

  2007cites this paper
• Dengue Virus Detection Using Whole Blood for Reverse Transcriptase PCR and Virus Isolation

  2007cites this paper
• Dengue vaccines approach the finish line.

  2007cites this paper
• Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1

  2007cites this paper
• Vaccines against dengue: a review of current candidate vaccines at advanced development stages.

  2007cites this paper